John Hancock Classic Value Fund Class R2 JCVSX

Medalist Rating as of | See John Hancock Investment Hub
  • NAV / 1-Day Return 21.51  /  −0.42 %
  • Total Assets 531.0M
  • Adj. Expense Ratio
    1.250%
  • Expense Ratio 1.270%
  • Distribution Fee Level Average
  • Share Class Type Retirement, Medium
  • Category Mid-Cap Value
  • Investment Style Mid Value
  • Min. Initial Investment 0
  • Status Open
  • TTM Yield 1.65%
  • Turnover 13%

USD | NAV as of Jul 18, 2026 | 1-Day Return as of Jul 18, 2026, 12:11 AM GMT+0

Morningstar’s Analysis JCVSX

Will JCVSX outperform in the future?

Get our overall rating based on a fundamental assessment of the pillars below.

null Morningstar Automated Analysis

Morningstar Automated Analysis

Summary

JHancock Classic Value R2 holds a quantitatively derived Neutral Morningstar Medalist Rating. The rating suggests the model does not express a clear expectation of outperformance or underperformance relative to peers over a full market cycle.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings JCVSX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 40.3
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

Humana Inc

6.42 34M
Healthcare

Baxter International Inc

4.83 26M
Healthcare

Usd

4.78 25M
Cash and Equivalents

Skyworks Solutions Inc

4.48 24M
Technology

CVS Health Corp

4.24 22M
Healthcare

Fresenius Medical Care AG ADR

3.57 19M
Healthcare

MetLife Inc

3.40 18M
Financial Services

Magna International Inc

3.39 18M
Consumer Cyclical

Lear Corp

3.36 18M
Consumer Cyclical

Cognizant Technology Solutions Corp Class A

3.31 17M
Technology

Sponsor Center